The World Health Organization (WHO) has resumed hydroxychloroquine trials for COVID-19, after reviewing safety concerns.
From the past two decades, the coronaviruses are spreading across the globe, attacking the respiratory system. They cause respiratory tract infections that can range from mild to deadly. The recent one is the novel coronavirus (COVID-19) is rapidly spreading across the globe. In May 2020, the research team from Brigham and Women’s Hospital had assessed real-life evidence for COVID-19 patients who received chloroquine or hydroxychloroquine. That time team stated that there is no strong evidence that either hydroxychloroquine reduced the mortality rate among COVID-19 patients. The research was published in the Lancet journal.
The veracity of the data was questioned immediately after the study was published. Now, after more than a week of questioning the integrity of the data, three of the four authors on the paper voluntarily withdrew it, following a controversial study that found chloroquine or hydroxychloroquine treatment is not safe or effective for COVID-19. For the time being, results published in the first randomized clinical testing suggest that it is no better than a placebo at preventing COVID-19. In May 2020, the team had noted that individuals who received chloroquine or hydroxychloroquine were more expected to experience rapid heart rhythms compared to those who had not received hydroxychloroquine.
A high risk of death from novel coronaviruses was found in thousands of COVID-19 patients treated with chloroquine or hydroxychloroquine. During that research, the researchers examined around 15,000 individuals from 671 hospitals across 6 continents and found that hydroxychloroquine treatment increases the risk of cardiovascular events and mortality. Moreover, at that time, the World Health Organization (WHO) had also recommended the discontinuation of hydroxychloroquine testing for COVID-19 treatment. However, now, WHO has resumed hydroxychloroquine trials for COVID-19, after reviewing safety concerns.